Novo Nordisk (0QIU) Gets a Buy from UBS
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Drugmakers agree to participate in second round of price negotiations
The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.
Tourmaline Bio price target raised to $43 from $42 at Wedbush
Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...
Council on Foreign Relations15h
American Pharmaceutical Companies Still Aren’t Paying Tax in the U.S.
K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.
Litigation Trends to Watch: COVID-19 Anniversary, Warranty Expiration Dates and Misuses of 401(k) Funds Trigger Lawsuits
Law.com Radar detected an uptick in securities cases centering on the COVID-19 pandemic. Eight federal lawsuits were surfaced ...